TrialAdvances in therapy2025

Efficacy and Safety Maintained up to 3 Years in Adults with Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan.

Carlos de Castro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.